EdgarLookup

AEHR TEST SYSTEMS — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that AEHR TEST SYSTEMS filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
-6.6%
Profit Margin
Net income ÷ revenue
-2.6%
Return on Assets
Net income ÷ assets
0.21x
Debt-to-Equity
Total liabilities ÷ equity
-10.9%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2025 May 30, 2025 $58.97M Jul 28, 2025
FY2025 May 31, 2024 $66.22M Jul 28, 2025
FY2025 May 31, 2023 $64.96M Jul 28, 2025
FY2022 May 31, 2022 $20.29M Aug 26, 2022
FY2022 Feb 28, 2022 $15.28M Aug 26, 2022
FY2022 Nov 30, 2021 $9.61M Aug 26, 2022
FY2022 Aug 31, 2021 $5.65M Aug 26, 2022
FY2022 May 31, 2021 $7.64M Aug 26, 2022
FY2022 Feb 28, 2021 $5.27M Aug 26, 2022
FY2022 Nov 30, 2020 $1.68M Aug 26, 2022

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2025 May 30, 2025 $58.97M Jul 28, 2025
FY2025 May 31, 2024 $66.22M Jul 28, 2025
FY2025 May 31, 2023 $64.96M Jul 28, 2025
FY2024 May 31, 2022 $50.83M Jul 30, 2024
FY2023 May 31, 2021 $16.60M Aug 28, 2023
FY2022 May 31, 2020 $22.29M Aug 26, 2022
FY2021 May 31, 2019 $21.06M Aug 27, 2021
FY2020 May 31, 2018 $29.56M Aug 28, 2020
FY2019 May 31, 2017 $18.90M Aug 28, 2019

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2025 May 30, 2025 $23.93M Jul 28, 2025
FY2025 May 31, 2024 $32.54M Jul 28, 2025
FY2025 May 31, 2023 $32.75M Jul 28, 2025
FY2022 May 31, 2022 $10.47M Aug 26, 2022
FY2022 Feb 28, 2022 $6.40M Aug 26, 2022
FY2022 Nov 30, 2021 $4.52M Aug 26, 2022
FY2022 Aug 31, 2021 $2.28M Aug 26, 2022
FY2022 May 31, 2021 $3.53M Aug 26, 2022
FY2022 Feb 28, 2021 $1.89M Aug 26, 2022
FY2022 Nov 30, 2020 $377.0K Aug 26, 2022

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 May 30, 2025 ($3.91M) Jul 28, 2025
FY2025 May 31, 2024 $33.16M Jul 28, 2025
FY2025 May 31, 2023 $14.56M Jul 28, 2025
FY2022 May 31, 2022 $5.79M Aug 26, 2022
FY2022 Feb 28, 2022 $2.24M Aug 26, 2022
FY2022 Nov 30, 2021 $717.0K Aug 26, 2022
FY2022 Aug 31, 2021 $696.0K Aug 26, 2022
FY2022 May 31, 2021 $567.0K Aug 26, 2022
FY2022 Feb 28, 2021 ($735.0K) Aug 26, 2022
FY2022 Nov 30, 2020 ($1.97M) Aug 26, 2022

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 May 30, 2025 ($5.68M) Jul 28, 2025
FY2025 May 31, 2024 $10.08M Jul 28, 2025
FY2025 May 31, 2023 $13.38M Jul 28, 2025
FY2024 May 31, 2022 $7.80M Jul 30, 2024
FY2023 May 31, 2021 ($4.18M) Aug 28, 2023
FY2022 May 31, 2020 ($2.77M) Aug 26, 2022
FY2021 May 31, 2019 ($5.00M) Aug 27, 2021
FY2020 May 31, 2018 $915.0K Aug 28, 2020
FY2019 May 31, 2017 ($4.93M) Aug 28, 2019
FY2018 May 31, 2016 ($6.15M) Aug 28, 2018

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 May 30, 2025 $10.46M Jul 28, 2025
FY2025 May 31, 2024 $8.72M Jul 28, 2025
FY2025 May 31, 2023 $7.13M Jul 28, 2025
FY2024 May 31, 2022 $5.82M Jul 30, 2024
FY2023 May 31, 2021 $3.65M Aug 28, 2023
FY2022 May 31, 2020 $3.39M Aug 26, 2022
FY2021 May 31, 2019 $4.15M Aug 27, 2021
FY2020 May 31, 2018 $4.18M Aug 28, 2020
FY2019 May 31, 2017 $4.66M Aug 28, 2019
FY2018 May 31, 2016 $4.32M Aug 28, 2018

SG&A Expense

Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.

Fiscal Year Period End Value Filed
FY2025 May 30, 2025 $18.28M Jul 28, 2025
FY2025 May 31, 2024 $13.75M Jul 28, 2025
FY2025 May 31, 2023 $12.24M Jul 28, 2025
FY2024 May 31, 2022 $10.05M Jul 30, 2024
FY2023 May 31, 2021 $6.56M Aug 28, 2023
FY2022 May 31, 2020 $7.53M Aug 26, 2022
FY2021 May 31, 2019 $7.72M Aug 27, 2021
FY2020 May 31, 2018 $7.29M Aug 28, 2020
FY2019 May 31, 2017 $7.05M Aug 28, 2019
FY2018 May 31, 2016 $6.98M Aug 28, 2018

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 May 30, 2025 ($7.40M) Jul 28, 2025
FY2025 May 31, 2024 $1.76M Jul 28, 2025
FY2025 May 31, 2023 $10.01M Jul 28, 2025
FY2024 May 31, 2022 $1.51M Jul 30, 2024
FY2023 May 31, 2021 ($2.70M) Aug 28, 2023
FY2022 May 31, 2020 ($2.02M) Aug 26, 2022
FY2021 May 31, 2019 ($5.64M) Aug 27, 2021
FY2020 May 31, 2018 ($1.35M) Aug 28, 2020
FY2019 May 31, 2017 ($4.50M) Aug 28, 2019
FY2018 May 31, 2016 ($6.28M) Aug 28, 2018

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 May 30, 2025 $4.99M Jul 28, 2025
FY2025 May 31, 2024 $749.0K Jul 28, 2025
FY2025 May 31, 2023 $1.36M Jul 28, 2025
FY2024 May 31, 2022 $416.0K Jul 30, 2024
FY2023 May 31, 2021 $227.0K Aug 28, 2023
FY2022 May 31, 2020 $163.0K Aug 26, 2022
FY2021 May 31, 2019 $173.0K Aug 27, 2021
FY2020 May 31, 2018 $572.0K Aug 28, 2020
FY2019 May 31, 2017 $477.0K Aug 28, 2019
FY2018 May 31, 2016 $919.0K Aug 28, 2018

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 May 30, 2025 $148.51M Jul 28, 2025
FY2025 May 31, 2024 $127.91M Jul 28, 2025
FY2024 May 31, 2023 $98.14M Jul 30, 2024
FY2023 May 31, 2022 $62.33M Aug 28, 2023
FY2022 May 31, 2021 $21.67M Aug 26, 2022
FY2021 May 31, 2020 $20.57M Aug 27, 2021
FY2020 May 31, 2019 $21.31M Aug 28, 2020
FY2019 May 31, 2018 $30.96M Aug 28, 2019
FY2018 May 31, 2017 $30.89M Aug 28, 2018
FY2017 May 31, 2016 $10.05M Aug 29, 2017

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 May 30, 2025 $25.64M Jul 28, 2025
FY2025 May 31, 2024 $16.32M Jul 28, 2025
FY2024 May 31, 2023 $22.54M Jul 30, 2024
FY2023 May 31, 2022 $11.34M Aug 28, 2023
FY2022 May 31, 2021 $10.22M Aug 26, 2022
FY2021 May 31, 2020 $6.52M Aug 27, 2021
FY2020 May 31, 2019 $5.85M Aug 28, 2020
FY2019 May 31, 2018 $11.67M Aug 28, 2019
FY2018 May 31, 2017 $14.10M Aug 28, 2018
FY2017 May 31, 2016 $10.77M Aug 29, 2017

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 May 30, 2025 $122.87M Jul 28, 2025
FY2025 May 31, 2024 $111.59M Jul 28, 2025
FY2025 May 31, 2023 $75.60M Jul 28, 2025
FY2025 May 31, 2022 $50.99M Jul 28, 2025
FY2024 May 31, 2021 $11.45M Jul 30, 2024
FY2023 May 31, 2020 $14.06M Aug 28, 2023
FY2020 May 31, 2019 $15.47M Aug 28, 2020
FY2019 May 31, 2018 $19.31M Aug 28, 2019
FY2018 May 31, 2017 $16.81M Aug 28, 2018
FY2017 May 31, 2016 ($703.0K) Aug 29, 2017

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 May 30, 2025 $10.72M Jul 28, 2025
FY2025 May 31, 2024 $0 Jul 28, 2025

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 May 30, 2025 ($23.06M) Jul 28, 2025
FY2025 May 31, 2024 ($19.15M) Jul 28, 2025
FY2024 May 31, 2023 ($52.31M) Jul 30, 2024
FY2023 May 31, 2022 ($66.86M) Aug 28, 2023
FY2022 May 31, 2021 ($76.31M) Aug 26, 2022
FY2021 May 31, 2020 ($74.29M) Aug 27, 2021
FY2020 May 31, 2019 ($71.48M) Aug 28, 2020
FY2019 May 31, 2018 ($66.25M) Aug 28, 2019
FY2018 May 31, 2017 ($66.78M) Aug 28, 2018
FY2017 May 31, 2016 ($61.12M) Aug 29, 2017

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 May 30, 2025 $24.53M Jul 28, 2025
FY2025 May 31, 2024 $49.16M Jul 28, 2025
FY2024 May 31, 2023 $30.05M Jul 30, 2024
FY2023 May 31, 2022 $31.48M Aug 28, 2023
FY2022 May 31, 2021 $4.58M Aug 26, 2022
FY2021 May 31, 2020 $5.43M Aug 27, 2021
FY2021 May 31, 2019 $5.43M Aug 27, 2021
FY2020 May 31, 2018 $16.85M Aug 28, 2020
FY2019 May 31, 2017 $17.80M Aug 28, 2019
FY2019 May 31, 2016 $939.0K Aug 28, 2019

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2018 May 31, 2018 $0 Aug 28, 2018
FY2018 May 31, 2017 $6.11M Aug 28, 2018
FY2017 May 31, 2016 $5.96M Aug 29, 2017
FY2016 May 31, 2015 $3.79M Aug 29, 2016
FY2015 May 31, 2014 $0 Aug 31, 2015

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 May 30, 2025 0 Jul 28, 2025
FY2025 May 31, 2024 1 Jul 28, 2025
FY2025 May 31, 2023 0 Jul 28, 2025
FY2022 May 31, 2022 0 Aug 26, 2022
FY2022 Feb 28, 2022 0 Aug 26, 2022
FY2022 Nov 30, 2021 0 Aug 26, 2022
FY2022 Aug 31, 2021 0 Aug 26, 2022
FY2022 May 31, 2021 0 Aug 26, 2022
FY2022 Feb 28, 2021 0 Aug 26, 2022
FY2022 Nov 30, 2020 0 Aug 26, 2022

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 May 30, 2025 0 Jul 28, 2025
FY2025 May 31, 2024 1 Jul 28, 2025
FY2025 May 31, 2023 0 Jul 28, 2025
FY2022 May 31, 2022 0 Aug 26, 2022
FY2022 Feb 28, 2022 0 Aug 26, 2022
FY2022 Nov 30, 2021 0 Aug 26, 2022
FY2022 Aug 31, 2021 0 Aug 26, 2022
FY2023 May 31, 2021 0 Aug 28, 2023
FY2022 May 31, 2020 0 Aug 26, 2022
FY2021 May 31, 2019 0 Aug 27, 2021

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 May 30, 2025 29.88M Jul 28, 2025
FY2025 May 31, 2024 29.00M Jul 28, 2025
FY2024 May 31, 2023 28.54M Jul 30, 2024
FY2023 May 31, 2022 27.12M Aug 28, 2023
FY2022 May 31, 2021 23,725 Aug 26, 2022
FY2021 May 31, 2020 23,107 Aug 27, 2021
FY2020 May 31, 2019 22,669 Aug 28, 2020
FY2019 May 31, 2018 22,143 Aug 28, 2019
FY2018 May 31, 2017 21.34M Aug 28, 2018
FY2017 May 31, 2016 13.22M Aug 29, 2017